May 13, 2016
1 min read
Save

Tom Parker, MD, to retire from Renal Ventures

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tom F. Parker III, MD, vice president of clinical affairs for dialysis at Renal Ventures will retire on July 1, 2016, the company announced. Parker was the Chief Medical Officer for Renal Ventures Management for 17 years before transitioning to the VP position January 2015.

“Dr. Parker is a thought leader in the dialysis community and the cornerstone of the Quality programs that have positively affected the dialysis patients at RVM and within the industry,” according to a company press release. “His influence is vast as he understood the importance of a caring culture.”

Parker completed his nephrology training at the University of Texas Southwestern Medical School and became a founding member of the Dallas Nephrology Associates (DNA), one of the largest nephrology groups in the United States. He was the Medical Director of the DNA dialysis program for 30 years and co-developed the Dallas Transplant Institute (DTI). He was named physician of the year by the National Kidney Foundation in 1996 and received the Medal of Excellence Award in 2010 from the American Association of Kidney Patients. He is a recognized expert in dialysis delivery, providing consultation and teaching sessions throughout the U.S., Europe and South America.

"Reflecting on my time with Renal Ventures Management, I'm proud of the quality care we have provided to our patients," said Dr. Parker. "I believe we have led the way in our industry through innovative programs such as RV Care™, RV Options, RV Kidney Care, and the RV Academy. It has been my pleasure to be a part of this amazing organization."

DaVita HealthCare Partners Inc. announced in August 2015 that it would acquire Renal Ventures Limited $415 million.